MapLight Shareholders Back Board Slate and Auditor
I'm LongbridgeAI, I can summarize articles.MapLight Therapeutics shareholders approved the board slate and auditor at their June 23, 2026 annual meeting. Approximately 86.56% of shares voted, electing Martin Babler, Troy Cox, and George Pavlov as directors until 2029. Investors also ratified RSM US LLP as the independent registered public accounting firm for fiscal year 2026. The vote reflects strong shareholder support for the company's governance and financial oversight.
An announcement from MapLight Therapeutics, Inc. ( (MPLT) ) is now available.
On June 23, 2026, MapLight Therapeutics stockholders held their 2026 annual meeting, with approximately 86.56% of the 42.6 million outstanding shares present or represented by proxy. Shareholders elected three directors—Martin Babler, Troy Cox and George Pavlov—to serve until the 2029 annual meeting, reinforcing continuity in the company’s board leadership.
Investors also ratified the appointment of RSM US LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with an overwhelming majority of votes in favor. The strong participation and decisive approvals signal broad shareholder support for MapLight’s governance structure and financial oversight framework.
The most recent analyst rating on (MPLT) stock is a Buy
with a $40.00 price target.
To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock,
see the MPLT Stock Forecast page.
Spark’s Take on MPLT Stock
According to Spark, TipRanks’ AI Analyst, MPLT is a Neutral.
The score is held back primarily by accelerating losses and cash burn despite a strong, low-debt balance sheet. Technicals are broadly neutral with only mild positive momentum, while traditional valuation support is limited due to negative earnings and no dividend. Recent corporate events add uncertainty given a missed Phase 2 primary endpoint and management turnover.
To see Spark’s full report on MPLT stock,
click here.
More about MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a biopharmaceutical company, and as a publicly traded entity it regularly engages with stockholders through annual meetings to elect directors and approve key corporate governance matters. The company operates under U.S. securities regulations, requiring detailed proxy disclosures and shareholder votes on its board composition and independent auditors.
Average Trading Volume: 321,238
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.27B
Learn more about MPLT stock on TipRanks’ Stock Analysis page.